Hello, everyone, and how are you today? We are coping so far, thank you. Despite gray skies hovering over the Pharmalot campus, our spirits are sunny. Our short person is in fine form today, as is the fast-growing official mascot, who is happily bounding about. And we are topping this off with another cup of stimulation. Our choice today is old-fashioned hazelnut. And so, on with the show. Here are a few items of interest to help brighten your own outlook. Hope all goes well today, and do keep in touch. …

The top five executives at Moderna (MRNA) have sold more than $89 million of stock so far this year — initiating nearly three times as many stock transactions than in all of 2019 — as the share price soared on hopes for its Covid-19 vaccine, STAT notes. The trades, which led to about $80 million in profits, were prescheduled through a legal program that allows company insiders to buy and sell shares at a later date. But the volume and timing might prove alarming to shareholders in light of a decision to raise more than $1 billion in a stock offering.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • One may observe that sometimes “timing the Market” can work out – and be jealous of their profits – but first it was just the CEO that was publicized, now a group. “Curioser and curioser” …..

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy